» Articles » PMID: 30642983

TCR Retrogenic Mice As a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C

Overview
Journal J Immunol
Date 2019 Jan 16
PMID 30642983
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Characterizing self-tolerance mechanisms and their failure is critical to understand immune homeostasis, cancer immunity, and autoimmunity. However, examination of self-tolerance mechanisms has relied primarily on transgenic mice expressing TCRs targeting well-characterized, but nonphysiologic, model Ags, such as OVA and hemagglutinin. Identifying TCRs directed against bona fide self-antigens is made difficult by the extraordinary diversity of TCRs and the low prevalence of Ag-specific clones (<10-100 naive cells per organism), limiting dissection of tolerance mechanisms restricting immunity to self-proteins. In this study, we isolated and characterized TCRs recognizing the intestinal epithelial cell receptor and colorectal cancer Ag GUCY2C to establish a model to study self-antigen-specific tolerance mechanisms. GUCY2C-specific CD4 effector T cells were isolated from immunized, nontolerant mice. Next-generation sequencing identified GUCY2C-specific TCRs, which were engineered into CD4 T cells in vitro to confirm TCR recognition of GUCY2C. Further, the generation of "retrogenic" mice by reconstitution with TCR-transduced hematopoietic stem cells resulted in normal CD4 T cell development, responsiveness to immunization, and GUCY2C-induced tolerance in recipient mice, recapitulating observations in conventional models. This retrogenic model can be employed to define self-tolerance mechanisms restricting T and B cell responses to GUCY2C to optimize colorectal cancer immunotherapy without autoimmunity.

Citing Articles

Guanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature.

Piroozkhah M, Aghajani A, Jalali P, Shahmoradi A, Piroozkhah M, Tadlili Y Front Oncol. 2023; 13:1277265.

PMID: 37927469 PMC: 10623427. DOI: 10.3389/fonc.2023.1277265.


T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.

Flickinger Jr J, Singh J, Yarman Y, Carlson R, Barton J, Waldman S Front Immunol. 2022; 13:855759.

PMID: 35355987 PMC: 8959893. DOI: 10.3389/fimmu.2022.855759.


GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Lisby A, Flickinger Jr J, Bashir B, Weindorfer M, Shelukar S, Crutcher M Expert Rev Precis Med Drug Dev. 2021; 6(2):117-129.

PMID: 34027103 PMC: 8133521. DOI: 10.1080/23808993.2021.1876518.


Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.

Flickinger Jr J, Singh J, Carlson R, Leong E, Baybutt T, Barton J J Immunother Cancer. 2020; 8(2).

PMID: 32819976 PMC: 7443303. DOI: 10.1136/jitc-2020-001046.


Generation of T Cell Receptor Retrogenic Mice.

Kong Y, Jing Y, Bettini M Curr Protoc Immunol. 2019; 125(1):e76.

PMID: 31090255 PMC: 6570547. DOI: 10.1002/cpim.76.


References
1.
Linnemann C, Heemskerk B, Kvistborg P, Kluin R, Bolotin D, Chen X . High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med. 2013; 19(11):1534-41. DOI: 10.1038/nm.3359. View

2.
Carrithers S, Parkinson S, Goldstein S, Park P, Urbanski R, Waldman S . Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors. Dis Colon Rectum. 1996; 39(2):171-81. DOI: 10.1007/BF02068072. View

3.
Holst J, Vignali K, Burton A, Vignali D . Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat Methods. 2006; 3(3):191-7. DOI: 10.1038/nmeth858. View

4.
Xiang B, Baybutt T, Berman-Booty L, Magee M, Waldman S, Alexeev V . Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8 T Cells. J Immunol. 2017; 198(9):3507-3514. PMC: 5435941. DOI: 10.4049/jimmunol.1502672. View

5.
Elliott J, Altmann D . Dual T cell receptor alpha chain T cells in autoimmunity. J Exp Med. 1995; 182(4):953-9. PMC: 2192287. DOI: 10.1084/jem.182.4.953. View